🇺🇸 FDA
Pipeline program

daclatasvir

AI444-406

Phase 3 small_molecule completed

Quick answer

daclatasvir for Hepatitis C is a Phase 3 program (small_molecule) at China SXT Pharmaceuticals with 1 ClinicalTrials.gov record(s).

Program details

Company
China SXT Pharmaceuticals
Indication
Hepatitis C
Phase
Phase 3
Modality
small_molecule
Status
completed

Clinical trials